{
    "organizations": [],
    "uuid": "affe387a0ff620de2dfbb8fad2f9bca5e2bfb539",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-announces/brief-adverum-biotechnologies-announces-long-term-preclinical-efficacy-data-on-advm-022-gene-therapy-in-wet-amd-idUSFWN1S809D",
    "ord_in_thread": 0,
    "title": "BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1 (Reuters) - Adverum Biotechnologies Inc:\n* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD\n* ADVERUM BIOTECHNOLOGIES - 13-MONTH DATA SHOW EFFICACY, DURABILITY OF PROTEIN EXPRESSION FOLLOWING A SINGLE INTRAVITREAL ADMINISTRATION OF ADVM-022\n* ADVERUM BIOTECHNOLOGIES INC - ADVM-022 WAS WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS IN STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T21:07:00.000+03:00",
    "crawled": "2018-05-02T15:58:22.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "adverum",
        "biotechnology",
        "inc",
        "adverum",
        "biotechnology",
        "announces",
        "preclinical",
        "efficacy",
        "data",
        "gene",
        "therapy",
        "wet",
        "amd",
        "adverum",
        "biotechnology",
        "data",
        "show",
        "efficacy",
        "durability",
        "protein",
        "expression",
        "following",
        "single",
        "intravitreal",
        "administration",
        "adverum",
        "biotechnology",
        "inc",
        "well",
        "tolerated",
        "serious",
        "adverse",
        "event",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}